BIHRPHA@EC2605A(24788.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
BIHRPHA@EC2605A
24788.HK
News
View More

JD's Shen Jiangguang: Rapid Development of Artificial Intelligence Infrastructure, Hong Kong Expected to Play a Greater Advantage

Jingdong Group Vice President Shen Jiangguang stated at the Asian Financial Forum that Hong Kong provides an international development environment for artificial intelligence companies, aiding in business expansion and innovation. With the rapid development of artificial intelligence infrastructure, Hong Kong is expected to play a greater role in fields such as data science, fintech, and intelligent manufacturing, becoming a strategic hub connecting mainland China and international markets. Meanwhile, HENGRUI PHARMA Vice Chairman Dai Hongbin emphasized the company's focus on Hong Kong's position in the international innovation ecosystem and looks forward to deepening cooperation to promote breakthroughs in biomedical technology

AASTOCKS·
HK
01276
-2.12%
SH
513120
-3.70%
HK
06618
-3.64%
AASTOCKS·
HK
01276
-2.12%
SH
513120
-3.70%
HK
06618
-3.64%

Hengrui Pharma Gets Nod for Solid Tumor Injection's Clinical Trials

Hengrui Pharma Gets Nod for Solid Tumor Injection's Clinical Trials

marketscreener·
HK
01276
-2.12%
SH
600276
-2.87%
marketscreener·
HK
01276
-2.12%
SH
600276
-2.87%

Morgan Stanley lowers Hengrui Pharma's revenue and net profit forecast, target price raised to 92 yuan

Morgan Stanley has lowered its revenue forecasts for Hengrui Pharma for 2025 to 2027, reducing them by 2.1%, 3.7%, and 1.8%, respectively, mainly due to a decrease in commercial development revenue from GlaxoSmithKline assets and a decline in contributions from the generic drug business, partially offset by an upward revision in innovative drug sales forecasts. Meanwhile, net profit forecasts have been lowered by 7.4%, 8.9%, and 6.5%. The target price has been raised from 86 yuan to 92 yuan, maintaining an "Overweight" rating

AASTOCKS·
HK
01276
-2.12%
SH
600276
-2.87%
SH
513120
-3.70%
AASTOCKS·
HK
01276
-2.12%
SH
600276
-2.87%
SH
513120
-3.70%

Hengrui Pharmaceuticals' Subsidiaries Get Nod to Trial Two Tumor Drugs

Hengrui Pharmaceuticals' Subsidiaries Get Nod to Trial Two Tumor Drugs

marketscreener·
SH
600276
-2.87%
HK
01276
-2.12%
marketscreener·
SH
600276
-2.87%
HK
01276
-2.12%

Hengrui Pharmaceuticals' Unit Gets Nod to Trial Diabetes Drugs

Hengrui Pharmaceuticals' Unit Gets Nod to Trial Diabetes Drugs

marketscreener·
HK
01276
-2.12%
SH
600276
-2.87%
SH
516820
-2.22%
marketscreener·
HK
01276
-2.12%
SH
600276
-2.87%
SH
516820
-2.22%
Posts
View More
© 2026 Longbridge｜Disclaimer